Current report
Open the filing on sec.gov
Kala Bio, Inc. (KALA)
Nasdaq: KALA · Pharmaceutical Preparations · Arlington, MA · filing with the SEC since 2009
The companyfiscal 2025, as filed
Revenue$0.00
Net income-$27.0M+29.9%
Earnings per share$-3.31+67.4%
Operating cash flow-$32.0M-8.9%
Cash$7.6M-85.2%
Debtn/a
Shareholders’ equity$7.0M-43.3%
Shares, diluted8,148,275+114.7%
Return on equity-385.6%
The recordfrom its filings
Filings in 202651
Newest filingNov 12 · 8-K
Annual reportApr 15, 2026
Quarterly reportAug 19, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$200,000
Insider buys, 12 months$0.00
Patents granted61
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income -$10.1MCash from operations -$19.9Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Results released
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Proxy statement
Open the filing on sec.gov
Preliminary proxy statement
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.